EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D

Results from the Phase III TRIUMPH-2 trial (NCT05929079) evaluating retatrutide in overweight patients with T2D were presented at EASD 2026. The trial evaluated Eli Lilly's retatrutide in adults with obesity or overweight and type 2 diabetes. Retatrutide is a once-weekly subcutaneous agonist of the GLP-1, GIP, and glucagon receptors. Credit: Anna Hoychuk via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI,…

Source: Clinical Trials Arena